WEST PALM BEACH, Fla., Nov. 1, 2016 /PRNewswire/ -- MDNA Life Sciences Inc. (MDNA), a molecular diagnostics company specializing in the development of blood-based diagnostic tests based on the mitochondrial genome, announced today that it has entered into a collaboration agreement with the University of Oxford to further the development and validation of MDNA's non-invasive blood-based test for endometriosis. The study will use MDNA's proprietary Mitomic Technology ™ to isolate mitochondrial biomarkers circulating in blood plasma that have the potential to accurately distinguish between women with and without endometriosis. The endometriosis test aims to provide the medical community with a much-needed tool in the management of endometriosis to close the average 9-year gap between symptom onset and diagnosis, and accelerate the pathway to treatment. Following the successful outcome of this clinical study, launch of the test is planned for 2017. The collaboration with the University of Oxford will be facilitated by Professor Christian Becker, and Professor Krina Zondervan, co-Directors of the Endometriosis Care and Research (CaRe) Centre which aims to find novel diagnostic approaches and identify innovative, more focused therapies for endometriosis. "This collaborative effort between MDNA Life Sciences and the Endometriosis CaRe Centre is an exciting novel project aiming to identify urgently needed biomarkers in endometriosis focusing on mitochondrial DNA," said Professor Becker. Professors Becker and Zondervan have also participated with the World Endometriosis Research Foundation (WERF) in the Endometriosis Phenome and Biobanking Harmonization Project (EPHect), which has produced the current standards in data, sample collection and processing for endometriosis research. "Using the WERF EPHect data and sample collection protocols will ensure the highest standards of phenotypic data and biological sample quality, which is a prerequisite for high quality and reproducible studies," added Professor Zondervan.